PGE1 is one of prostaglandins which inhibit platelet functions and have vasodilating activity as well as PGI2. Newly developed PGE1 analogue (ONO-1206) was supplied for the clinical evaluations by Ono Pharmaceutical Company. This research was performed to analyze the effect of orally administered ONO-1206 on platelet functions and to evaluate the usefulness on the thromboembolic disorders.
Comparing with PGI2, this analogue demonstrated the similar inhibitory activity on the platelet aggregation in the in vitro study. Oral administration of ONO-1206 on the patients with thromboembolic disorders showed the dose-dependent inhibition on platelet aggregation and adhesiveness. This activity continued for 180min. (max. at 120min.). Daily oral administration (20μg or 30μg t. i. d.) was continued for two weeks and its effect on blood pressure, heart rate, platelet aggregation, platelet adhesiveness, and platelet c-AMP level were evaluated. Both of administration doses caused remarkable depression of platelet aggregation and increase of platelet c-AMP level and mild suppression on the platelet adhesiveness. Blood pressure was decreased in almost all cases but heart rate remained unchanged. Clinical improvement of symptoms were observed in the patients with deep vein thrombosis or angina pectoris.
These results suggest the effectiveness and usefulness of this oraly administered PGE1 analogue against the prevention and treatment of thromboembolic disorders.